Amundi lowered its holdings in shares of Chemed Co. (NYSE:CHE - Free Report) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,790 shares of the company's stock after selling 11,340 shares during the quarter. Amundi owned approximately 0.25% of Chemed worth $20,105,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Impax Asset Management Group plc increased its holdings in Chemed by 4.7% in the 3rd quarter. Impax Asset Management Group plc now owns 332,757 shares of the company's stock valued at $199,977,000 after acquiring an additional 14,814 shares during the last quarter. Venturi Wealth Management LLC increased its holdings in shares of Chemed by 59.8% in the third quarter. Venturi Wealth Management LLC now owns 425 shares of the company's stock worth $255,000 after purchasing an additional 159 shares during the last quarter. Aigen Investment Management LP purchased a new stake in shares of Chemed in the third quarter worth about $300,000. First Heartland Consultants Inc. boosted its stake in Chemed by 7.2% during the third quarter. First Heartland Consultants Inc. now owns 508 shares of the company's stock valued at $305,000 after buying an additional 34 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in Chemed by 0.7% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 13,277 shares of the company's stock valued at $7,979,000 after buying an additional 92 shares in the last quarter. Institutional investors own 95.85% of the company's stock.
Shares of NYSE:CHE traded up $8.19 during trading on Friday, reaching $598.15. The company's stock had a trading volume of 92,073 shares, compared to its average volume of 101,073. The stock has a market capitalization of $8.76 billion, a PE ratio of 30.22, a price-to-earnings-growth ratio of 2.15 and a beta of 0.43. Chemed Co. has a 12 month low of $512.12 and a 12 month high of $654.62. The firm's 50 day simple moving average is $559.02 and its two-hundred day simple moving average is $564.62.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Monday, February 24th will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, February 24th. This represents a $2.00 annualized dividend and a yield of 0.33%. Chemed's payout ratio is presently 10.05%.
In other news, VP Brian C. Judkins purchased 145 shares of the business's stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average cost of $519.50 per share, for a total transaction of $75,327.50. Following the acquisition, the vice president now owns 1,678 shares of the company's stock, valued at approximately $871,721. This trade represents a 9.46 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $593.67, for a total transaction of $1,187,340.00. Following the completion of the sale, the chief executive officer now directly owns 102,679 shares of the company's stock, valued at approximately $60,957,441.93. The trade was a 1.91 % decrease in their position. The disclosure for this sale can be found here. 3.32% of the stock is owned by corporate insiders.
Several brokerages have recently issued reports on CHE. Royal Bank of Canada upped their price objective on Chemed from $633.00 to $667.00 and gave the stock an "outperform" rating in a report on Friday. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research report on Friday, March 7th.
Get Our Latest Stock Report on CHE
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.